"Identification and Characterization of Diagnostic and Prognostic Biomarkers for Brain Tumors"
Study Objective: To combine the knowledge from the published literature and Valley’s own research experience to identify, compile and test a panel of potential diagnostic and prognostic biomarkers for brain tumors.
Principal Investigator: Anthony D'Ambrosio, M.D.
"Randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed GBM with MGMT promoter hypermethylation"
Study Objective: Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ (temozolomide), compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed glioblastoma multiforme (GBM) patients with tumor O-6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter hypermethylation.
Arm 1: Chemo + veliparib (investigational PARP inhibitor)
Arm 2: Chemo + placebo
Principal Investigator: Eli Kirshner, M.D.
Click here for more information on A071102
The Valley Hospital Biorepository
For The Valley Hospital (TVH) patients undergoing surgical procedures, we offer the opportunity to participate in TVH Biorepository. This protocol involves the freezing and storage of extra tissue not used for diagnosis, blood and other bodily fluids that may be used for future research designed to develop or contribute to generalized knowledge in cancer research. Available to all persons diagnosed with cancer, having surgery for excision, and is strongly encouraged.